Home » BioInvent and Cambridge Antibody Technology Sign Licensing Agreement
BioInvent and Cambridge Antibody Technology Sign Licensing Agreement
BioInvent International AB announced that it has entered into a license agreement with Cambridge Antibody Technology. Under the agreement BioInvent and its partners receive rights to use CAT's antibody phage display patent estate to develop products from BioInvent's n-CoDeRÒ antibody libraries. As part of the agreement BioInvent has agreed to withdraw its opposition to CAT's patents filed at the European Patent Office in Munich.
()a href="http://www.bioportfolio.com/news/bioinvent_2.htm" target="_blank">BioPortfolio
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May